Minimally Invasive Aesthetic Treatments for the Corrective Patient Archetype: Transforming Lives

The definition of health encompasses mental, emotional, and social well-being, rather than simply the absence of disease. As a result, corrective aesthetic treatments are increasingly being viewed as an integral component of overall health rather than confined solely to the domain of aesthetics. In the realm of facial aesthetics, the corrective patient archetype is distinctly focused on rebalancing or proportioning facial features to improve confidence and self-perception. Minimally invasive treatments, such as botulinum toxin and hyaluronic acid (HA) gels, are known for their efficacy, tolerability, and ability to improve psychological and social outcomes. Additionally, hybrid injectables are gaining traction for their immediate filling and lifting effects that also provide biostimulating effects over time in the injected area.

Here, we present a clinical review of the literature, accompanied by examples that illustrate the practical application of onabotulinumtoxinA, HA gels, and hybrid injectables (HA and calcium hydroxyapatite; Allergan Aesthetics, an AbbVie Company) for patients seeking corrections, including facial asymmetries (e.g., facial paralysis and hemifacial microsomia), trauma, and scarring, emphasizing the importance of tailored approaches to achieve optimal outcomes.

OnabotulinumtoxinA, HA gels, and hybrid injectables were effective, tolerable, and enhanced patients' quality of life by addressing both aesthetic and functional concerns. Overall, further research is needed to refine these treatments and expand their applications in corrective aesthetic medicine.

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors  www.springer.com/00266 .